The Protein Arginine N Methyltransferase 5 pipeline drugs market research report outlays comprehensive information on the Protein Arginine N Methyltransferase 5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Protein Arginine N Methyltransferase 5 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Hematological Disorders which include the indications Solid Tumor, Non-Small Cell Lung Cancer, and Unspecified Hematological Disorders. It also reviews key players involved in Protein Arginine N Methyltransferase 5 targeted therapeutics development with respective active and dormant or discontinued products.
The Protein Arginine N Methyltransferase 5 pipeline targets constitutes close to 39 molecules. Out of which, approximately 38 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 5, 6, 5, 18, and 4 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Protein Arginine N Methyltransferase 5 overview
Protein arginine N-methyltransferase 5 (PRMT5) is an enzyme that is encoded by the PRMT5 gene in humans. PRMT5 is an epigenetic enzyme that mainly represses transcription of target genes via symmetric dimethylation of arginine residues on histones. PRMT5 regulates developmental homeostatic and disease processes in vertebrates and invertebrates.
For a complete picture of Protein Arginine N Methyltransferase 5’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
